Free Trial

Synlogic (SYBX) Competitors

Synlogic logo
$1.59 -0.08 (-4.79%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$1.61 +0.02 (+1.51%)
As of 07/25/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SYBX vs. ADVM, PDSB, ANVS, ANL, GANX, NRXP, ATRA, KRON, CELU, and VTVT

Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Adverum Biotechnologies (ADVM), PDS Biotechnology (PDSB), Annovis Bio (ANVS), Adlai Nortye (ANL), Gain Therapeutics (GANX), NRx Pharmaceuticals (NRXP), Atara Biotherapeutics (ATRA), Kronos Bio (KRON), Celularity (CELU), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

Synlogic vs. Its Competitors

Adverum Biotechnologies (NASDAQ:ADVM) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Adverum Biotechnologies currently has a consensus target price of $23.80, suggesting a potential upside of 781.48%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than Synlogic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Synlogic
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 6.0% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 3.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Adverum Biotechnologies had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Adverum Biotechnologies and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.89 beat Adverum Biotechnologies' score of 1.56 indicating that Synlogic is being referred to more favorably in the news media.

Company Overall Sentiment
Adverum Biotechnologies Very Positive
Synlogic Very Positive

Synlogic's return on equity of 10.91% beat Adverum Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adverum BiotechnologiesN/A -130.53% -66.31%
Synlogic N/A 10.91%7.47%

Synlogic has lower revenue, but higher earnings than Adverum Biotechnologies. Synlogic is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$1M56.40-$130.93M-$6.40-0.42
Synlogic$10K1,860.30-$23.36M-$2.51-0.63

Adverum Biotechnologies has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500.

Summary

Adverum Biotechnologies beats Synlogic on 8 of the 15 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYBX vs. The Competition

MetricSynlogicMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.53M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-0.6321.1828.1020.05
Price / Sales1,860.30288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book1.468.378.665.87
Net Income-$23.36M-$55.19M$3.25B$258.55M
7 Day Performance-8.62%5.88%4.23%3.74%
1 Month Performance30.33%17.33%10.52%11.75%
1 Year Performance-4.79%4.42%34.41%18.03%

Synlogic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYBX
Synlogic
1.3093 of 5 stars
$1.59
-4.8%
N/A-5.4%$19.53M$10K-0.6380Positive News
Gap Up
ADVM
Adverum Biotechnologies
4.5009 of 5 stars
$2.73
+7.5%
$23.80
+771.8%
-66.6%$57.03M$1M-0.43190News Coverage
Positive News
PDSB
PDS Biotechnology
1.2455 of 5 stars
$1.23
-0.8%
$9.00
+631.7%
-70.1%$56.22MN/A-1.3120
ANVS
Annovis Bio
1.8523 of 5 stars
$2.87
+5.7%
$18.00
+528.3%
-72.1%$55.84MN/A-1.333
ANL
Adlai Nortye
1.897 of 5 stars
$1.51
-6.2%
$9.00
+496.0%
-57.6%$55.72M$5M0.00127
GANX
Gain Therapeutics
2.3564 of 5 stars
$1.86
+7.5%
$8.20
+340.9%
+62.5%$55.71M$50K-2.1620Gap Up
NRXP
NRx Pharmaceuticals
2.5358 of 5 stars
$3.21
flat
$28.50
+787.9%
+28.2%$55.50MN/A-1.602
ATRA
Atara Biotherapeutics
4.6337 of 5 stars
$9.30
+0.8%
$17.75
+90.9%
+18.6%$55.44M$199.73M-2.50330News Coverage
Positive News
KRON
Kronos Bio
N/A$0.88
+1.5%
$1.63
+84.7%
-34.3%$53.72M$9.85M-0.82100
CELU
Celularity
0.1409 of 5 stars
$2.24
+6.2%
N/A-1.0%$53.65M$54.22M-0.85220News Coverage
Upcoming Earnings
VTVT
vTv Therapeutics
1.54 of 5 stars
$16.71
-1.8%
$35.50
+112.4%
-26.6%$53.31M$1.02M-5.559News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:SYBX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners